Clinical Trial Will Test Effect Of Epidiolex On Cognition In Children With Rare Epilepsy

  • GW Pharmaceuticals plans to recruit approximately 116 children with Lennox-Gastaut Syndrome to participate in a new clinical trial.
  • The study will examine the effects of Epidiolex on the cognition of participants, aged 3 to 10 years.
  • Cognition is any form of information processing, mental operation, or intellectual activity such as thinking, reasoning, remembering, imagining, or learning.
  • Recruitment for the open-label, exploratory trial is expected to begin December, 2019. Estimated primary completion is December, 2020.